In summary, we identify SKP2 as a pharmacologic tumor vulnerability in FN-RMS, as testified by the very low sensitivity of normal myoblasts and fibroblasts to the SKP2 inhibiting compounds, as already reported in other tumors17,64. This evidence concerns the gene SKP2 and neoplasm.